Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $419000.0.

  • CytomX Therapeutics' Change in Account Payables fell 4833.54% to $419000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$695000.0, marking a year-over-year decrease of 9093.41%. This contributed to the annual value of -$297000.0 for FY2024, which is 7917.25% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Change in Account Payables stood at $419000.0, which was down 4833.54% from -$49000.0 recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Change in Account Payables registered a high of $3.3 million during Q3 2022, and its lowest value of -$2.4 million during Q4 2022.
  • Its 5-year average for Change in Account Payables is -$117263.2, with a median of -$261000.0 in 2024.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 66153.85% in 2021, then surged by 187567.57% in 2022.
  • Over the past 5 years, CytomX Therapeutics' Change in Account Payables (Quarter) stood at $1.2 million in 2021, then crashed by 294.67% to -$2.4 million in 2022, then surged by 86.18% to -$328000.0 in 2023, then grew by 20.43% to -$261000.0 in 2024, then skyrocketed by 260.54% to $419000.0 in 2025.
  • Its Change in Account Payables stands at $419000.0 for Q3 2025, versus -$49000.0 for Q2 2025 and -$804000.0 for Q1 2025.